The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.

Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D

Diabetes, obesity & metabolism3 Jan 2021Cited by 319 (Europe PMC)

PMID33269530PMCIDPMC7898914DOI10.1111/dom.14280PepBankPUB-33269530

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg increased the paracetamol AUC over 0 to 5 hours by 8% versus placebo at week 20.
In plain wordsIn adults with obesity, semaglutide 2.4 mg slightly raised a paracetamol absorption measure of stomach emptying compared with placebo.
Peptide
Semaglutide
Outcome
IncreaseParacetamol AUC 0-5 h (gastric emptying), primary endpoint
Study
n = 72
Comparator
Placebo
Analysis
Primary
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Paracetamol AUC0-5h increase
8%
semaglutide 2.4 mg vs placebo, week 20
Source sentences
Summary
The area under the concentration-time curve (AUC) for paracetamol 0 to 5 hours after a standardized meal (AUC_0-5h,para ; primary endpoint) was increased by 8% (P = 0.005) with semaglutide 2.4 mg versus placebo at week 20
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953001
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the paracetamol AUC difference with semaglutide 2.4 mg was not significant when corrected for week 20 body weight.
In plain wordsIn adults with obesity, the small stomach-emptying difference with semaglutide was not significant after adjusting for body weight.
Peptide
Semaglutide
Outcome
No significant changeParacetamol AUC 0-5 h corrected for body weight
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Measurements
P value
0.12
corrected for body weight
Source sentences
Summary
(non-significant when corrected for week 20 body weight; P = 0.12)
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953002
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg had no effect on paracetamol AUC 0-1 h, maximum concentration or time to maximum concentration versus placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg did not change early paracetamol absorption measures compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeParacetamol AUC 0-1 h, Cmax and tmax
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
No effect was seen on AUC_0-1h,para , maximum observed paracetamol concentration, or time to maximum observed paracetamol concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953003
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, ad libitum energy intake was 35% lower with semaglutide 2.4 mg than with placebo.
In plain wordsIn adults with obesity, people ate about a third less at a free lunch with semaglutide 2.4 mg than with placebo.
Peptide
Semaglutide
Outcome
DecreaseAd libitum energy intake
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Energy intake difference
35%
semaglutide vs placebo
Estimated treatment difference
−940 kJ
semaglutide vs placebo
Source sentences
Summary
Ad libitum energy intake was 35% lower with semaglutide versus placebo (1736 versus 2676 kJ; estimated treatment difference -940 kJ; P <0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953004
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg reduced hunger compared with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg reduced hunger compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseHunger
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953005
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg reduced prospective food consumption compared with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg lowered how much people expected to eat, compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseProspective food consumption
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953006
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg increased fullness compared with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg increased fullness compared with placebo.
Peptide
Semaglutide
Outcome
IncreaseFullness
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953007
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide 2.4 mg increased satiety compared with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg increased satiety compared with placebo.
Peptide
Semaglutide
Outcome
IncreaseSatiety
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger and prospective food consumption, and increased fullness and satiety when compared with placebo (all P <0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953008
09HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the Control of Eating Questionnaire showed better control of eating with semaglutide 2.4 mg than with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg gave better control of eating than placebo.
Peptide
Semaglutide
Outcome
IncreaseControl of eating (CoEQ)
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
The CoEQ indicated better control of eating and fewer/weaker food cravings with semaglutide versus placebo (P <0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953009
10HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the Control of Eating Questionnaire showed fewer and weaker food cravings with semaglutide 2.4 mg than with placebo.
In plain wordsIn adults with obesity, semaglutide 2.4 mg gave fewer and weaker food cravings than placebo.
Peptide
Semaglutide
Outcome
DecreaseFood cravings (CoEQ)
Study
n = 72
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
The CoEQ indicated better control of eating and fewer/weaker food cravings with semaglutide versus placebo (P <0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953010
11HumanRandomized controlled trialEfficacy outcome
In adults with obesity, body weight was reduced by 9.9% with semaglutide 2.4 mg and 0.4% with placebo.
In plain wordsIn adults with obesity, body weight fell much more with semaglutide 2.4 mg than with placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 72
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Measurements
Body weight reduction
9.9%
semaglutide 2.4 mg
Body weight reduction
0.4%
placebo
Source sentences
Summary
Body weight was reduced by 9.9% with semaglutide and 0.4% with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953011
12HumanRandomized controlled trialSafety outcome
In adults with obesity, the safety of semaglutide 2.4 mg was consistent with the known profile of semaglutide.
In plain wordsIn adults with obesity, semaglutide 2.4 mg safety matched what is already known for semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSafety
Study
n = 72
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
2.4 mg once weekly (dose-escalated) · subcutaneous · 20 weeksAs given in this study (human).
Source sentences
Summary
Safety was consistent with the known profile of semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A double-blind, parallel-group trial was conducted in 72 adults with obesity, randomized to once-weekly s.c. semaglutide (dose-escalated to 2.4 mg) or placebo for 20 weeks.
Report a problemFND-3326953012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT03842202

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Novo Nordisk A/Sn = 7215 Feb 2019 to 4 Nov 2019

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 24 Dec 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.